T. Rowe Price Investment Management, Inc. Black Diamond Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 6,725,365 shares of BDTX stock, worth $38 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
6,725,365
Previous 3,927,879
71.22%
Holding current value
$38 Million
Previous $11 Million
208.91%
% of portfolio
0.02%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
36.5MCall Options Held
29.6KPut Options Held
5K-
Bellevue Group Ag Kuesnacht, V88.52MShares$48.1 Million0.68% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$25.1 Million1.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.91MShares$10.8 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.6MShares$9.06 Million0.99% of portfolio
-
Black Rock Inc. New York, NY1.38MShares$7.8 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $205M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...